Development and clinical applications of a method for measuring apoE-rich HDL-C

胆固醇酯转移蛋白（CETP）抑制剂使高密度脂蛋白（HDL）浓度增加，其颗粒大小大，载脂蛋白（apo） E含量丰富，被称为“富载脂蛋白高密度脂蛋白”。然而，迄今为止还没有发表的关于测量富含载脂蛋白e的高密度脂蛋白和抗动脉粥样硬化功能（如去除胆固醇的能力）的技术的研究。在这项研究中，我们利用CETP缺乏或胆汁淤积患者的血清样本证明了富含载脂蛋白e的高密度脂蛋白的抗动脉粥样硬化作用，这些患者与CETP抑制剂等这类脂蛋白水平升高有关。此外，我们开发了一种测量总高密度脂蛋白胆固醇（HDL- c）的方法，包括使用非离子表面活性剂，聚烷基二醇，对这种高密度脂蛋白具有高特异性。

Cholesteryl ester transfer protein(CETP) inhibitors increase the concentration of HDL having large particle size and an abundance of apolipoprotein(apo) E, which is known as"apoE-rich HDL". However, there have been no published studies to date on techniques for measuring apoE-rich HDL and anti-atherogenic functions such as the ability removing cholesterol. In this study, we demonstrated the anti-atherogenic action of apoE-rich HDL using serum samples from patients with CETP deficiency or cholestasis associated with elevated levels of this type of lipoprotein like CETP inhibitors. Furthermore, we developed a method for measuring total HDL cholesterol(HDL-C) including apoE-rich HDL using a nonionic surfactant, a polyalkylene glycol, with high specificity for this HDL.